Search filters

Filters
Clear All

Phase

  • 14
  • 13
  • 15
  • 7
  • 12
  • 70
  • 28
  • 1
  • 69

Found 70 Lung Disease trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Pilot study for functional and structural MR Imaging of Endobroncial valve recipients using hyperpoloarized XENON-129
99 years or below
All genders
We propose to use gas Magnetic Resonance Imaging (MRI) using the inhaled contrast agent, hyperpolarized (HP) xenon-129, to study the lungs of 20 volunteers who have received or will receive endobronchial valve (EBV) therapy as a treatment for COPD. Since its recent FDA approval, investigators have yet to explicitly assess …
99 years or below
All genders
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
18 years - 99 years
All genders
The DECAMP 1 PLUS study will expand on previous early detection studies (DECAMP 1 and 2) to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules. This study will investigate molecular, clinical and imaging features that may distinguish benign versus malignant disease among smokers with indeterminate …
 Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
Surgery is the best treatment for patients with Stage I or II lung cancer; however, nearly 60% of patients have recurrence. Additional immunotherapeutic agents given before surgery may be greatly reduce recurrence. This is a Standard Phase I, 3+3 dose escalation trial designed to evaluate the safety and toxicity of …
 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
99 years or below
All genders
Phase 1
Normal 0 false false false EN-US X-NONE X-NONE You are being invited to participate in a research study because you have Bronchiolitis Obliterans Syndrome. Bronchiolitis Obliterans Syndrome (BOS) is a long term (chronic) rejection process that can occur in the transplanted lungs.  Itacitinib works by blocking your body from producing …
99 years or below
All genders
Phase 2
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
99 years or below
All genders
Phase 2
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
99 years or below
All genders
Phase 1
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …
99 years or below
All genders
The primary objective of the study is to evaluate the safety and effectiveness of the NEUWAVETM FLEX MC Microwave Ablation System and Accessories used in transbronchial ablation procedures for adult subjects with oligometastatic tumors ( 2cm) in the lung. Technique Efficacy: Ablation of the target tumor(s) with the ablation zone …
 A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 2
Interventional
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design